CALIXAR team will attend at the online Redefining Early Stage Investments (RESI) event, from June 8 to 10, 2021 to present its new licensing business model and to develop its pipeline of native targets of pharmaceutical interest.
CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format.
The biotech company wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025.
About the Redefining Early Stage Investments (RESI)
The Redefining Early Stage Investments (RESI) conference series connect start-ups and early-stage investors and strategic channel partners. The RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development. The RESI is uniquely cross-border and cross-domain, connecting start-ups with 10 categories of global investors across the silos of drugs, devices, diagnostics and digital health (4 Ds).
For more information and meet us: Redefining Early Stage Investments (RESI)